These effects are interconnected to the physiological and pathological processes of Alzheimers disease (AD), hypertension, and non-alcoholic steatohepatitis (NASH)
In the phase 2 programs, retatrutide improved several of these parameters beyond weight and glucose, including blood pressure and lipid measures, alongside the dramatic reductions in liver fat
Exercise: Both aerobic and resistance exercise acutely increase GLP-1 secretion
The design integrates several key components, as outlined below: the chosen CBBBP is Tat, identified through prior animal experimentation from two candidate peptides for its superior efficacy in facilitating the transport of therapeutic agents crossing BBB
Side effect comparison: Nausea: Similar rates between the two compounds Vomiting: Cagrilintide significantly lower (OR 0.38) Diarrhea: Comparable rates Constipation: Similar Injection site reactions: Cagrilintide substantially higher Discontinuation due to AEs: Cagrilintide much lower (1% vs approximately 5-7%) The takeaway: if vomiting was your main problem on semaglutide, cagrilintide may be worth exploring